A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
AssigneesWUXI Biologics (Shanghai) Co., Ltd., Wuxi Biologics Ireland Limited, Open Monoclonal Technology, Inc.
InventorsYong ZHENG, Jingjing LIU, Jing LI
Life of this patent
Estimating the term…
Abstract
Provided are novel fully human monoclonal antibodies that bind to human 4-1BB. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-4-1BB antibodies, vectors and host cells used for the expression of anti-4-1BB antibodies. The invention further provides methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of invention provide a very potent agent for the treatment of multiple cancers via modulating human immune function.
Claims21
-40. (canceled)
An isolated antibody against 4-1BB or the antigen-binding portion thereof, wherein the isolated antibody or the antigen-binding portion thereof comprises:
- A) one or more heavy chain CDRs (CDRHs) selected from at least one of the group consisting of:
- (i) a CDRH1 with at least 90% sequence identity to a CDRH1 as set forth in one of the sequences selected from the group consisting of SEQ ID NOs:
- 1 and 7;
- (ii) a CDRH2 with at least 90% sequence identity to a CDRH2 as set forth in one of the sequences selected from the group consisting of SEQ ID NOs:
- 2 and 8;
- and
- (iii) a CDRH3 with at least 90% sequence identity to a CDRH3 as set forth in one of the sequences selected from the group consisting of SEQ ID NOs:
- 3 and 9;
- B) one or more light chain CDRs (CDRLs) selected from at least one of the group consisting of:
- (i) a CDRL1 with at least 90% sequence identity to a CDRL1 as set forth in one of the sequences selected from the group consisting of SEQ ID NOs:
- 4 and 10;
- (ii) a CDRL2 with at least 90% sequence identity to a CDRL2 as set forth in one of the sequences selected from the group consisting of SEQ ID NOs:
- 5 and 11;
- and
- (iii) a CDRL3 with at least 90% sequence identity to a CDRL3 as set forth in one of the sequences selected from the group consisting of SEQ ID NOs:
- 6 and 12;
- or
- C) one or more CDRHs of A) and one or more CDRLs of B).
Dependencies are inferred from the claim text.